Navigation Links
European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Date:6/16/2008

Worldwide COGENT-1 Study of CGT-2168 Expands to Europe; Focus on Reducing

Gastrointestinal Side Effects of Antiplatelet Therapy

MENLO PARK, Calif., June 16 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc. today announced that the first patient has been enrolled in Europe in the company's pivotal Phase 3 study of its novel combination medicine CGT-2168. The patient entered the COGENT-1 study at the Zadebie cardiology clinic in Skierniewice, Poland.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO)

The study, which began in North America in January, is evaluating the antiplatelet medicine CGT-2168, a combination of clopidogrel (currently marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis as Plavix(R)) and a gastroprotectant (omeprazole) in a single pill. Developed by Cogentus, CGT-2168 is designed to provide cardiovascular benefits while reducing potentially serious gastrointestinal side effects commonly associated with dual antiplatelet therapy.

Antiplatelet therapy is an integral part of treating patients with acute coronary syndrome and has been shown to be effective in preventing major cardiovascular events. However, the combination of clopidogrel and aspirin is associated with gastrointestinal bleeding, which in some cases requires hospitalization and can even result in death.

"Millions of cardiac patients in Europe have benefited from antiplatelet therapy," said Gilles Montalescot, M.D., Ph.D., Professor of Cardiology at the Institut de Cardiologie, Pitie-Salpetriere Hospital in Paris. "It is important that our patients have access to innovative new treatment options that can enhance compliance with treatment and provide positive outcomes. We look forward to being part of the COGENT program."

Among the estimated 4,000 patients worldwide who will participate in the study, approximately half will receiv
'/>"/>

SOURCE Cogentus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. XTENT Announces European Regulatory Update
2. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
3. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
4. European Unions CHMP Issues Positive Opinion on Sugammadex
5. PLC Systems Announces Approval of First European Study to Evaluate RenalGuard(TM)
6. PRoFESS(R) Results Announced at XVII European Stroke Conference
7. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
8. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
9. European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
10. More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
11. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014  Amgen (NASDAQ: ... Sanders Williams , M.D., president of Gladstone Institutes and ... "We are pleased to welcome Dr. ... Robert A. Bradway , chairman and chief executive ... in academic medicine and his direct experience in our ...
(Date:10/17/2014)... October 17, 2014 ... Market by Technique (Optical Coherence Tomography, Hyperspectral ... Application (Ophthalmology, Neurology, Oncology, Cardiology) - Global ... studies the Optical Imaging market over the ... valued at $917.1 million in 2014 and ...
(Date:10/17/2014)... Md. , Oct. 17, 2014 ... for Medical Technology Policy: The Green ... the FDA, public and private payers, medical device ... clinicians, and other experts January 12, 2015 at ... and value of weight loss treatments.  Participants will ...
Breaking Medicine Technology:Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3Optical Imaging Market Worth $1,669.2 Million by 2019 2Optical Imaging Market Worth $1,669.2 Million by 2019 3Optical Imaging Market Worth $1,669.2 Million by 2019 4Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2
... NEW YORK, Aug. 14 Immtech Pharmaceuticals,Inc. (Amex: ... paper published in Nucleic,Acids Research by a group ... ability of furamidine to inhibit a key enzyme ... Furamidine is the active metabolite (DB75),of Immtech,s proprietary, ...
... Scheduled Start of Phase 3 Clinical Trial, BELTSVILLE, ... has reported a second quarter 2007 loss from continuing,operations ... to a loss from,continuing operations of $699,000, or 5 ... from discontinued operations in the second quarter,of 2007 was ...
Cached Medicine Technology:Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 3Spherix Reports Second Quarter Earnings 2
(Date:10/20/2014)... San Diego, CA (PRWEB) October 20, 2014 ... regarding all the latest information from the FDA on ... consumers on October 10 not to purchase or use Sit ... Phenolphthalein. Sit and Slim II is promoted as weight loss ... , Sibutramine, removed from the market in 2010 for safety ...
(Date:10/20/2014)... 20, 2014 National Teen Driver Safety Week ... American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is ... parents of teen drivers to talk to their teens and ... Motor vehicle crashes are the leading cause of death for ... in fatal crashes, and 859 (42%) of those teen drivers ...
(Date:10/20/2014)... Houston, Texas (PRWEB) October 20, 2014 ... invited to present the key elements of his innovative ... visiting professor to plastic surgery residents and faculty at ... (UTMB) , where he, too, was once a medical ... of the largest private cosmetic plastic surgery practices in ...
(Date:10/19/2014)... UNITED NATIONS, New York (PRWEB) October 19, 2014 ... the United Nations Population Fund, welcomes news of a ... release of the more than 200 girls who were ... Girls. "These girls have languished in captivity long enough, ... their families, schools and communities," stated Dr. Osotimehin. , ...
(Date:10/19/2014)... October 20, 2014 SweetDressy.com, a professional ... announced its promotion for long evening dresses . ... the special offer; the current discount is up to ... the industry pioneers in the fashion field. Its dress ... ladies dwelling in various parts of the world. All ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... the number of primary care physicians in medically underserved ... who often exhibit a strong sense of responsibility for ... new study by UCLA researchers and colleagues published in ... Public Health . Training these students ...
... By Steven Reinberg HealthDay Reporter , ... a booster shot of the vaccine that protects against ... The panel made the recommendation because the vaccine ... In 2007, the U.S. Centers for Disease Control ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, Oct. ... the dangers associated with high blood pressure and many are ... known as hypertension, hasn,t changed in a decade, health officials ... the U.S. Centers for Disease Control and Prevention, 30 percent ...
... research published today, researchers uncover evolution in action in ... pancreatic tumours mean that not only is cancer genetically ... cancer spread within a patient has acquired distinct mutations. ... are ten different, but related, tumours. The complexity of ...
... Scientists are reporting development of a new approach for dealing ... simply mask odors like today,s room fresheners, but eliminates them ... from nanoparticles hundreds of times smaller than peach fuzz ... gold standard. A report on these next-generation odor-fighters appears in ...
... (HealthDay News) -- People who regularly eat whole grains rather ... fat linked to a higher risk for heart disease and ... visceral adipose tissue (VAT) -- the fat that surrounds the ... blood pressure, high cholesterol and insulin resistance, health risk factors ...
Cached Medicine News:Health News:Doctors' sense of mission, self-identity key in choice to work in underserved areas 2Health News:Teens Should Get Meningitis Booster Shot: CDC Panel 2Health News:Percentage of U.S. Adults With Hypertension Holds Steady at 30% 2Health News:Forces for cancer spread: Genomic instability and evolutionary selection 2Health News:Forces for cancer spread: Genomic instability and evolutionary selection 3Health News:Eating Whole Grains, Fewer Refined Grains, May Help Heart 2
Headlight module is mounted on UltraLite Plus headband....
... rapid rise in intracranial ... intervention and continuous monitoring. ... technology that gets to ... Its versatility makes it ...
The MPM-1 offers a broad range of functions to attain new levels of parenchymal and ventricular monitoring through fiberoptic technology at the source....
... Codman ICP Monitoring System ... of intracranial pressure at ... intraventricular levels. The information ... than through a hydrostatic ...
Medicine Products: